- Home
- CRGX vs FRST Comparison
CRGX vs FRST Comparison
Compare CRGX & FRST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- FRST
- Stock Information
- Founded
- CRGX 2021
- FRST 2004
- Country
- CRGX United States
- FRST United States
- Employees
- CRGX N/A
- FRST N/A
- Industry
- CRGX
- FRST Major Banks
- Sector
- CRGX
- FRST Finance
- Exchange
- CRGX Nasdaq
- FRST Nasdaq
- Market Cap
- CRGX 190.0M
- FRST 220.5M
- IPO Year
- CRGX 2023
- FRST 2006
- Fundamental
- Price
- CRGX $4.25
- FRST $9.47
- Analyst Decision
- CRGX Hold
- FRST Buy
- Analyst Count
- CRGX 7
- FRST 1
- Target Price
- CRGX $4.67
- FRST $420.00
- AVG Volume (30 Days)
- CRGX 569.8K
- FRST 96.4K
- Earning Date
- CRGX 05-08-2025
- FRST 07-24-2025
- Dividend Yield
- CRGX N/A
- FRST 4.21%
- EPS Growth
- CRGX N/A
- FRST N/A
- EPS
- CRGX N/A
- FRST 0.16
- Revenue
- CRGX N/A
- FRST $125,133,000.00
- Revenue This Year
- CRGX $58.18
- FRST $21.33
- Revenue Next Year
- CRGX N/A
- FRST $12.77
- P/E Ratio
- CRGX N/A
- FRST $58.98
- Revenue Growth
- CRGX N/A
- FRST 22.34
- 52 Week Low
- CRGX $3.00
- FRST $7.59
- 52 Week High
- CRGX $25.45
- FRST $13.52
- Technical
- Relative Strength Index (RSI)
- CRGX 53.57
- FRST 58.38
- Support Level
- CRGX $3.78
- FRST $9.37
- Resistance Level
- CRGX $4.27
- FRST $9.71
- Average True Range (ATR)
- CRGX 0.18
- FRST 0.23
- MACD
- CRGX 0.03
- FRST 0.03
- Stochastic Oscillator
- CRGX 88.79
- FRST 62.50
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About FRST Primis Financial Corp.
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit.